06821 ASYMCHEM
- 39.250
- -0.950-2.36%
ASYMCHEM News
Founder Securities: the revenue growth rate of the pharmacy sector slows down, and the concentration is expected to accelerate.
The individual account reform of medical insurance has led to a decrease in personal account income, affecting pharmaceutical sales and pharmacy business relying on individual account payments. In 2023, pharmacy medical insurance personal account expenditures decreased by 9%, and this trend is expected to continue in 2024.
gtja: The new signed orders for CXO in the first half of the year show a positive trend, and the API profitability is improving gradually by quarter.
In the first half of the year, CXO performance is under short-term pressure, with a positive trend in new signings; the API destocking is nearing completion, and profitability is improving quarter by quarter.
Is the chain of pharmacies entering a "mini ice age"? H1 growth rate "downgrades", the industry's high-growth stores may reach turning point.
① The growth rate of sales revenue of all categories in retail pharmacies has slowed down, and the competition in stock continues to intensify. In the first half of this year, it was difficult for major chain pharmacies to increase revenue and profit. ② In the future, the focus of pharmacy competition will shift to commodity extension and services. According to the prediction of Zhongkang Industry Research Institute, the growth rate of pharmaceuticals in all end terminals in 2024 is expected to decrease to 4.9%, a decrease from 2023.
Asymchem Laboratories (002821.SZ): Cumulatively repurchased 3.5976% of shares.
Asymchem Laboratories (002821.SZ) announced on September 2 that, as of August 30, 2024, the company has cumulatively repurchased a total of 12,300,701 shares of the company's stock through a repurchase special securities account through centralized bidding, accounting for 3.5976% of the company's total A-share capital. The highest fill price was 102.00 yuan/share and the lowest fill price was 71.65 yuan/share. The total amount paid was 999,644,601.56 yuan (excluding transaction costs). This share repurchase is in compliance with the company's repurchase plan and relevant laws and regulations.
Will you be eliminated if you don't go overseas? In the first half of the year, the proportion of innovative drug outbound business development accounted for about 80% | Industry Dynamics.
①At the 2024 New Investment Conference hosted by Frost Sullivan, the issue of going global was favored by participants. ②There is a new trend in the export of innovative drugs in China, for example, the number of export BDs exceeded License-in for the first time in 2023. ③Some participating experts put forward rational opinions and called for internal strength, not just enthusiasm.
Asymchem Laboratories (Tianjin)'s H1 Attributable Profit Falls 70%; Shenzhen Shares Rise 4%
Hong Kong stocks soar with the collective rise of CRO concept stocks, as the Federal Reserve is expected to cut interest rates and new industry orders are accelerating recovery.
CRO concept stocks rose collectively, as of the publication, Joinn Laboratories (06127) rose 2.96% to HKD 7.3; Wuxi AppTec (02359) rose 2.56% to HKD 34.05; Asymchem Laboratories (06821) rose 2.5% to HKD 40.95.
Gloria Ying: 2024 Semi-Annual Report Summary
Gloria Ying: 2024 Semi-Annual Report
Asymchem Laboratories (06821) plans to apply for a comprehensive credit limit of no more than 2.3 billion yuan.
Asymchem Laboratories (06821) announced that, in view of the expiration of the company and its subsidiaries' bank credit limits, in order to ensure the extension of credit...
Asymchem Laboratories Faces Sharp Profit Decline
Asymchem Laboratories (06821.HK) reported a net income of 0.499 billion yuan for the mid-year, a 70.40% decrease year-on-year.
On August 28, Gelonghui announced that in the middle of 2024, Asymchem Laboratories' total revenue was RMB 26,550.5 million, a slight decrease of 0.26% year-on-year after excluding substantial orders. The gross margin for the full year of 2024 was 41.23%, a decrease of 11.57 percentage points compared to the same period last year, mainly due to the higher gross margin of substantial orders delivered in 2023 and a significant decrease in the gross margin of emerging businesses. The revenue of small molecule CDMO business was RMB 21,534.2 million, a year-on-year increase of 1.09% after excluding substantial orders. In addition, the new...
Asymchem Laboratories (06821) announced its interim results, with a net profit attributable to the parent company of approximately 0.499 billion yuan, a year-on-year decrease of 70.4%.
Asymchem Laboratories (06821) announced its mid-term performance for 2024, with revenue of 2.655 billion yuan, a decrease of 42.23% year-on-year...
Asymchem Laboratories (002821.SZ) released its first-half performance, with a net income of 0.499 billion yuan, a decrease of 70.40%.
Asymchem Laboratories (002821.SZ) released its 2024 interim report, during the reporting period, the company achieved revenue of 2...
ASYMCHEM: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024
Express News | Asymchem Laboratories H1 Net Profit Down 70.4% Y/Y
We Think Asymchem Laboratories (Tianjin) (SZSE:002821) Can Stay On Top Of Its Debt
Asymchem Laboratories (06821): 0.05754 million restricted shares will be listed and traded from August 27th.
Asymchem Laboratories (06821) announced the release of a portion of the reserved grants for the 2020 restricted stock incentive plan.
Hong Kong stock market anomaly | Asymchem Laboratories (06821) fell more than 4%, leading the CRO concept. The industry's performance is generally under pressure due to the decline in investment and financing in the pharmaceutical industry.
CRO concept stocks fell today. As of press time, Asymchem Laboratories (06821) fell 3.74%, at HKD 39.9; Tigermed (03347) fell 3.67%, at HKD 30.2; Pharmaron (03759) fell 3.06%, at HKD 8.55; Wuxi AppTec (02359) fell 2.88%, at HKD 32.05.
Sinolink: The results of the negotiations on drug prices in the United States have been announced, and the continuous procurement of medical devices domestically is ongoing.
Bullish on the development of the domestic medical devices industry in the second half of the year, with the industry's purchasing demand expected to accelerate recovery. At the same time, domestic leading companies in sub-sectors such as ultrasound and endoscopy, due to their strong competitiveness, are expected to further increase market share, with sales growth and profitability expected to return to an upward trend.
Analysis
Price Target
No Data
